Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transforming growth factor beta receptor I (TGFBR1), also known as activin A receptor type II-like kinase 5 (ALK-5), is a membrane-bound serine/threonine protein kinase and a key component of the TGF-beta receptor family. It plays a central role in mediating cellular responses to members of the transforming growth factor beta (TGF-β) superfamily, which are multifunctional cytokines involved in regulating cell proliferation, differentiation, apoptosis, and other critical processes. Upon ligand binding, TGFBR1 propagates intracellular signaling by phosphorylating downstream effectors such as R-Smad proteins. Dysregulation can contribute to diseases such as cancer progression or fibrotic disorders. Mutations in TGFBR1 are associated with Loeys–Dietz syndrome.
Small-molecule inhibitors targeting TGFBR1 kinase activity, blocking downstream signaling.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transforming Growth Factor Beta Receptor I (TGFBR1).